SAN DIEGO, April 18, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, today previewed a case series to be presented at the 2017 National Kidney Foundation (NKF) Spring Clinical Meeting, which begins today and continues through April 22. Physicians will present data on two biomarkers, TIMP-2 and IGFBP-7, used to assess risk for acute kidney injury (AKI) during the management of patients with acute decompensated heart failure (ADHF).
Elevated levels of TIMP-2 and IGFBP-7 have been shown to signal kidney stress indicative of AKI risk.1 Physicians used Astute Medical's NephroCheck® Test, which detects the biomarkers in a urine sample and delivers an AKIRisk® score, to proactively assess patient risk of developing moderate to severe AKI, with the goal of preventing injury and the resultant loss of kidney function.
In a recent review of the literature,2 authors noted that with more than 1 million hospitalizations and costs exceeding $30 billion, ADHF has reached epidemic proportions in the United States. Renal dysfunction is a strong predictor of adverse outcomes in ADHF, with AKI occurring in approximately one-third of patients with ADHF (designated CRS1). Assessment of risk for AKI during the management of ADHF may provide the physician with valuable information about the patient that can impact treatment decisions.3
NKF Spring Clinical Meeting attendees can learn more about the NephroCheck® Test at Astute Medical's exhibition booth #231.
Details of the presentation follow:
|
Topic: Acute Kidney Injury/ICU Medicine | |
|
Abstract: |
Assessing the role of TIMP2 & IGFBP7 in forecasting AKI risk in congestive |
|
Primary |
Sanjeev Gupta, M.D. |
|
Poster #: |
9 |
Important Information About The NephroCheck® Test
The NephroCheck® Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are intensive care unit (ICU) patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment. The NephroCheck® Test System is intended to be used in patients 21 years of age or older.
Astute Medical's NephroCheck Test received 510(k)-clearance through the FDA's de novo classification. The test is CE-marked and available in Europe.
For additional information visit NephroCheck.com.
About Astute Medical, Inc.
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.
Astute Medical is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025.
For additional information, please visit AstuteMedical.com.
Astute Medical®, the AM logo, Astute140®, NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see astutemedical.com/US/About/IntellectualProperty/. PN0643 Rev A 2017/04/14
1 Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and dark sides. Nephrol Dial Transplant (2015) 0: 1–7doi: 10.1093/ndt/gfv130.
2 Prins KW, Thenappan T, Markowitz JS, Pritzker MR. Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure. JCOM. October 2015 Vol. 22, No. 10.
3 Schanz M, Shi J, Wasser C, Alscher MD and Kimmel M. Urinary [TIMP-2] Å~ [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Clin Cardiol. 2017. https://doi.org/10.1002/clc.22683.
SOURCE Astute Medical, Inc.